PFE.N
Latest Trade
43.56USDChange
0.41(+0.95%)Volume
10,645,130Today's Range
-
43.7652 Week Range
-
51.86As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 43.15 |
|---|---|
Open | 43.17 |
Volume | 10,645,130 |
3M AVG Volume | 688.51 |
Today's High | 43.76 |
Today's Low | 42.94 |
52 Week High | 51.86 |
52 Week Low | 33.36 |
Shares Out (MIL) | 5,606.69 |
Market Cap (MIL) | 241,984.70 |
Forward P/E | 10.49 |
Dividend (Yield %) | 3.61 |
U.S. CDC Says Delivered 503,418,475 Doses Of Covid-19 Vaccine As Of Oct 25
U.S. CDC Says Administered 413,645,478 Doses Of Covid-19 Vaccine As Of Oct 24
U.S. CDC Says Delivered 501,613,665 Doses Of Covid-19 Vaccine As Of Oct 22
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'amelio
Chief Financial Officer, Executive Vice President - Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Payal Sahni
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 19.72 |
|---|---|
Price To Sales (TTM) | 4.36 |
Price To Book (MRQ) | 3.45 |
Price To Cash Flow (TTM) | 13.97 |
Total Debt To Equity (MRQ) | 56.03 |
LT Debt To Equity (MRQ) | 50.48 |
Return on Investment (TTM) | 8.93 |
Return on Equity (TTM) | 7.16 |
An expert panel on Tuesday voted overwhelmingly to recommend the U.S. Food and Drug Administration authorize the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages 5 to 11, saying the benefits of the shot outweigh the risks.
The U.S. Food and Drug Administration's committee of outside experts will weigh in on authorisation of Pfizer Inc and BioNTech SE's COVID-19 vaccine for emergency use in children aged 5-11.
Scientists at the U.S. Food and Drug Administration (FDA) said on Friday that the likely benefits of giving the Pfizer/BioNTech COVID-19 vaccine to 5 to 11 year olds clearly outweigh the risks of rare cases of heart inflammation.
The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11 year olds, the U.S. drugmaker said on Friday.
A booster dose of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE restored efficacy to 95.6% against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday.
Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
The Pfizer Inc/BioNTech SE COVID-19 vaccine was 93% effective in preventing hospitalizations among those aged 12 to 18, according to an analysis released by the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday.
* Also OKs ready-to-use formulation for the shot, Comirnaty (Adds details on site, formulation approval, background)
Europe's drug regulator said https://bit.ly/3BXTBfy on Monday it has approved two more manufacturing sites for producing the COVID-19 vaccine developed by Pfizer Inc <PFE.N and BioNTech, while also approving a ready-to-use formulation of the coronavirus shot. (Reporting...
The European Union's medicines regulator said on Monday it has started evaluating the use of Pfizer Inc and BioNTech's COVID-19 vaccine in children between the ages of five and 11.
A top U.S. Food and Drug Administration official said on Friday that the agency is considering lowering the recommended age for who should receive booster shots of the Pfizer/BioNTech COVID-19 vaccine to as young as 40 years old, based on data from Israel suggesting the...
Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize their COVID-19 vaccine for emergency use in children aged 5-11, with an expert panel to the Food and Drug Administration scheduled to meet later this month to review data.
Pfizer Inc and German partner BioNTech SE said on Friday that they had submitted data supporting the use of their COVID-19 vaccine in children aged between five and less than 12 years to the European Medicines Agency.
Pfizer Inc and German partner BioNTech SE said on Friday that they had submitted data supporting an application for use of their COVID-19 vaccine in children aged 5 to 12 years to the European Medicines Agency.
Israel health officials on Thursday said booster doses of the Pfizer-BioNTech COVID-19 vaccine improved severe disease protection in people aged 40 and older, in presentations made to U.S. scientists discussing a booster dose of Moderna's vaccine.
Booster doses of the Pfizer Inc. -BioNTech SE COVID-19 vaccine improved severe disease protection in people aged 40 and older, Israel's Health Ministry told an outside panel of the U.S. Food and Drug Administration on Thursday.
Panama has approved a booster dose of Pfizer Inc's COVID-19 vaccine for high-risk people, including healthcare workers, bedridden patients, nursing home residents and people over 55, health officials said on Tuesday.
Italy has decided to provide a booster shot of Pfizer and BioNTech's COVID-19 vaccine to frail people regardless of their age as well as people aged 60 and over, the health ministry said on Friday.
Independent advisers to the U.S. Centers for Disease Control and Prevention will meet later this month to make recommendations on booster doses of Moderna Inc and Johnson & Johnson's COVID-19 vaccines, the agency said on Friday.
Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize emergency use of their COVID-19 vaccine for children ages 5 to 11, a group for whom no shot is currently allowed, Pfizer said on Thursday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.